Journal of Endocrinological Investigation

, Volume 22, Issue 8, pp 636–640 | Cite as

Effect of SERMs on breast tissue

  • Steven R. Goldstein
Article

Key-words

SERMs breast tissue breast cancer estrogen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gallup survey findings: overview of perceived and real health threats. Gallup Survey, 1995.Google Scholar
  2. 2.
    Cancer Facts & Figures-1998. Atlanta, American Cancer Society, 1998.Google Scholar
  3. 3.
    1998 Heart and Stroke Statistical Update. Dallas, American Heart Association, 1998.Google Scholar
  4. 4.
    Feuer E.J., Wun L.-M., Boring C.C., Flanders W.D., Timmel M.J., Tong T. The lifetime risk of developing breast cancer. J. Natl. Cancer Inst. 1993, 85: 892–897.PubMedCrossRefGoogle Scholar
  5. 5.
    US Bureau of the Census. Population projections of the United States by age, sex, race, and hispanic origin: 1995 to 2050. In: Current Population Reports. Washington, Government Printing Office, 1996 48, 72, 78, 80, 88. Series P25–1130.Google Scholar
  6. 6.
    National Center for Health Statistics. Current Estimates from the National Health Interview Survey: 1992. Hyattsville, Md: US Dept of Health and Human Services; 1994, 115. Series 10, No 189. DHSS Publications No. (PHS) 94–1517.Google Scholar
  7. 7.
    Hammond C.B. Women’s concerns with hormone replacement therapy compliance issues. Fertil. Steril. 1994, 62 (Suppl. 2): 157S–160S.PubMedGoogle Scholar
  8. 8.
    Morrow M. Breast cancer: Who and Why? In: Jordan V.C. (ed.), Tamoxifen. A Guide for Clinicians and Patients. Huntington, New York., PRR, Inc. 1996, p. 1–14.Google Scholar
  9. 9.
    Bret K.M., Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 1997, 145: 536–545.CrossRefGoogle Scholar
  10. 10.
    Ravnikar V.A. Compliance with hormone replacement therapy: are women receiving the full impact of hormone replacement therapy preventative health benefits? Womens Health Issues 1992, 2: 75.PubMedCrossRefGoogle Scholar
  11. 11.
    Bryant H.U., Dere W.H. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 1998, 217: 45–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldstein S.R., Scheele W.H., Symanowski S.M., Neale S., Shah A., Lafortune M., et al. Uterine safety considerations for selective estrogen receptor modulators. Menopause 1977, 4: 250.CrossRefGoogle Scholar
  13. 13.
    Goldstein S.R., Srikanth R., Parsons A.K. Effects of Raloxifene on the endometrium in healthy postmenopausal women. J. Ultrasound Med. 1999, 18: S111.Google Scholar
  14. 14.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047–1059.CrossRefGoogle Scholar
  15. 15.
    Jordan V.C. Designer estrogens. Sci. Am. 1998, 279: 60–67.PubMedCrossRefGoogle Scholar
  16. 16.
    Colditz G.A., Hankinson S.E., Hunter D.J., Willet W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332: 1589–1593.PubMedCrossRefGoogle Scholar
  17. 17.
    Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 1995, 13: 513–529.PubMedGoogle Scholar
  18. 18.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 1988, 319: 1681–1692.CrossRefGoogle Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351: 1415–1467.Google Scholar
  20. 20.
    Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998, 339: 1609–1618.PubMedCrossRefGoogle Scholar
  21. 21.
    Lippman M.E., Osborne C.K., Knazek R., Young N. In vitro model systems for the study of hormone-dependent human breast cancer. N. Engl. J. Med. 1977, 296: 154–159.PubMedCrossRefGoogle Scholar
  22. 22.
    Osborne C.K., Hobbs K., Clark G. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985, 45: 584–590.PubMedGoogle Scholar
  23. 23.
    Jordan V.C. Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylebezanthracene (DMBA) — induced rat mammary carcinoma mode. J. Steroid Biochem. 1974, 5: 354.CrossRefGoogle Scholar
  24. 24.
    Jordan V.C., Allen K.E. Evaluation of the antitumor activity of the non steroidal antiestrogen monohydroxytamoxifen in the DMBA induced rat mammary carcinoma mode. Eur. J. Cancer 1980, 16: 239–251.PubMedCrossRefGoogle Scholar
  25. 25.
    Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., Mulvi Hill J.J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 1989, 81: 1879–1886.PubMedCrossRefGoogle Scholar
  26. 26.
    Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer. Inst. 1998, 90: 1371–1388.PubMedCrossRefGoogle Scholar
  27. 27.
    Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tudy A., Viggers J., Davey J. Interim analysis of incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998, 352: 98–101.PubMedCrossRefGoogle Scholar
  28. 28.
    Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Roberston C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Prevention Study Lancet 1998, 352: 93–97.Google Scholar
  29. 29.
    Short L.L., Glasebrook A.L., Adrian M.D., et al. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J. Bone Miner. Res. 1996, 11 (Suppl. 1): S482.Google Scholar
  30. 30.
    Sato M., Glasebrook A., Bryant H.U. Raloxifene: a selective estrogen receptor modulator. J. Bone Miner. Metab. 1994, 12 (Suppl. 2): S9–S20.CrossRefGoogle Scholar
  31. 31.
    Hol T., Cox M.B., Bryant H.U., Draper M.W. Selective estrogen receptor modulators and postmenopausal women’s health. J. Womens Health 1997, 6: 523–531.PubMedCrossRefGoogle Scholar
  32. 32.
    Buzdar A.U., Marcus C., Holmes F., Hug V., Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988, 45: 344–345.PubMedCrossRefGoogle Scholar
  33. 33.
    Killackey M., Hakes T., Pierce V. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 1985, 69: 237–238.PubMedGoogle Scholar
  34. 34.
    Jordan V.C. Tamoxifen and endometrial cancer [Letter]. Lancet 1989, 2: 117–20.Google Scholar
  35. 35.
    Neven P., Muylder X., Van Belle Y., Vanderick G., De Mylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 1990, 35: 235–238.PubMedCrossRefGoogle Scholar
  36. 36.
    Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C. The effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Jordan V.C., Glusman J.E., Eckert S., et al. Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double blind, randomized trials in postmenopausal women. Abstract presented at the 21st Annual San Antonio Breast Cancer Symposium. San Antonio, December 12–15, 1998.Google Scholar
  38. 38.
    Cummings S.R., Norton L., Eckert S., et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc. Am. Soc. Clin. Oncol. 1998, 17. Abstract 3.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1999

Authors and Affiliations

  • Steven R. Goldstein
    • 1
  1. 1.New York University Medical CenterNew YorkUSA

Personalised recommendations